Ernexa Therapeutics (ERNAW) Long-Term Debt Repayments (2010 - 2020)

Ernexa Therapeutics has reported Long-Term Debt Repayments for 11 years, with the latest figure at -$2.0 million in Q4 2020.

• For the quarter ending Q4 2020, Long-Term Debt Repayments fell 910.0% year-over-year to -$2.0 million; the trailing twelve-month figure through Dec 2020 stood at -$305000.0 (down 130.5% YoY), and the FY2023 full-year result was $1.5 million, changed N/A from the prior year.
• Long-Term Debt Repayments for Q4 2020 stood at -$2.0 million, down from $750000.0 in the prior quarter.
• The five-year high for Long-Term Debt Repayments was $5.2 million in Q4 2018, with the low at -$2.7 million in Q4 2017.
• Historically, Long-Term Debt Repayments has averaged $311176.5 across 5 years, with a median of $250000.0 in 2019.
• Annual changes were most pronounced in 2018 — Long-Term Debt Repayments soared 293.97% — and 2020, when it slumped 910.0%.
• Ernexa Therapeutics' Long-Term Debt Repayments stood at -$1.5 million in 2016, then tumbled by 81.71% to -$2.7 million in 2017, then soared by 293.97% to $5.2 million in 2018, then sank by 95.23% to $250000.0 in 2019, then tumbled by 910.0% to -$2.0 million in 2020.
• The last three Long-Term Debt Repayments figures came in at -$2.0 million (Q4 2020), $750000.0 (Q1 2020), and $250000.0 (Q4 2019), per Business Quant data.